A US-based KOL discusses the current therapeutic landscape in CML, highlighting key unmet needs and positioning of existing marketed therapies. Pipeline agents were also assessed in terms of clinical potential and anticipated uptake, alongside expected shifts in the treatment paradigm upon approval.

This interview was conducted on January 26, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.